Search

Your search keyword '"Fracanzani, Anna L."' showing total 110 results

Search Constraints

Start Over You searched for: Author "Fracanzani, Anna L." Remove constraint Author: "Fracanzani, Anna L."
110 results on '"Fracanzani, Anna L."'

Search Results

1. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

2. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models

3. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

4. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension

5. Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

6. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

7. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

8. Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

9. Relation between drug therapy-based comorbidity indices, Charlson's comorbidity index, polypharmacy and mortality in three samples of older adults

11. Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

12. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

14. Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients

15. Initiation of Psycholeptic Medication During Hospitalization With Recommendation for Discontinuation After Discharge

16. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

17. Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients

18. Comparison between drug therapy-based comorbidity indices and the Charlson Comorbidity Index for the detection of severe multimorbidity in older subjects

19. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

21. Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients

22. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models

23. Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients

24. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study

26. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

29. Impact of natural neuromedin‐B receptor variants on iron metabolism

30. Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register

31. Inappropriate prescription of benzodiazepines in acutely hospitalized older patients

33. Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards

34. Liver fibrosis by FibroScan ® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes

35. Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients

36. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

38. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

39. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease

43. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

47. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver

48. Hepatic steatosis and PNPLA3 I148 M variant are associated with serum Fetuin- A independently of insulin resistance.

Catalog

Books, media, physical & digital resources